Class summary at a glance.

Every drug in the Noncompetitive AMPA Glutamate Receptor Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $113.0Mcombined across class
Total Rx claims: 91K13K unique beneficiaries
Generic mfrs (active): 3across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Perampanel

Brand: Fycompa · 91K Part D claims (CY24) · 13K beneficiaries · First FDA approval: 2012-10-22

3 generic mfrs 1288 plans require PA

Low NADAC$4.46

→

Avg plan cost$28.37

Part D spend $113.0M 6× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.